Pharmaceutical major Sanofi India has come under the scrutiny of state indirect tax authorities following the issuance of a substantial show cause notice alleging discrepancies in its tax credit claims. The Commercial Tax Officer (Audit)-6.1, DGSTO-6, Bengaluru, served the notice under the Karnataka Goods and Services Tax (KGST) Act, 2017, demanding a cumulative sum of ₹23.74 crore. The action highlights the intensifying regulatory oversight governing indirect tax assessments, reconciliation workflows, and statutory input tax credit (ITC) mechanisms across large-scale corporate enterprises.
Details of the Notice and Fiscal Breakdown
Dated September 25, 2026, the demand originates from an audit assessment covering the financial year 2022-23 (April 2022 to March 2023). The Karnataka GST authorities have alleged that the multinational healthcare company claimed excess input tax credit during this period.
The total demand of ₹23.74 crore comprises two distinct components:
- Proposed Principal Tax Liability: ₹14.43 crore
- Accrued Interest: ₹9.31 crore
The notice has been framed under Section 73 of the Karnataka Goods and Services Tax Act, 2017, a provision invoked in cases involving tax unpaid, short paid, or ITC wrongly availed or utilized for reasons other than fraud, willful misstatement, or suppression of facts.
The Mechanics of Section 73 and ITC Scrutiny
The invocation of Section 73 rather than the more punitive Section 74 signifies that tax authorities view the matter as a regular dispute over statutory interpretation or clerical and reconciliation differences rather than deliberate evasion. Nonetheless, the financial exposure remains notable, particularly due to the compounding effect of statutory interest charges over multi-year assessment cycles.
Under India’s indirect tax framework, input tax credit serves as the foundational mechanism to avoid cascading taxation. For large manufacturers and distributors, credit availability is tied to rigorous multi-tiered validations. As businesses operate complex supply chains, managing vendor invoices, reverse charge obligations, and credit reconciliations becomes central to mitigating dispute risks, a dynamic echoed across sectors seeking stability through GST-driven credit and domestic competitiveness.
Departmental audits under the Goods and Services Tax framework frequently cross-examine data across several statutory returns, identifying variances between the credit claimed by the taxpayer and the credit reflected in official vendor filings. When audits detect mismatches or unverified vendor entries for an entire fiscal year, authorities typically propose full reversals along with applicable interest.
The Impact of Accrued Interest on Corporate Exposure
A striking aspect of the notice served to Sanofi India is the proportion of interest relative to the underlying tax demand. At ₹9.31 crore, the interest constitutes nearly 39% of the total ₹23.74 crore liability. This underscores how protracted audit timelines and retrospective reconciliations can significantly escalate the monetary cost of disputed credits.
For corporate treasuries and compliance teams, managing interest exposure is a critical element of fiscal discipline. With interest under GST statutes accruing automatically from the date credit is utilized until the date of payment, any extended disagreement over eligibility can result in finance costs that rival the underlying tax claim. This dynamic aligns with broader treasury challenges where firms must balance liquidity, working capital allocations, and statutory liabilities in an evolving financial climate, as detailed in our analysis on corporate treasury and GST compliance dynamics.
Sanofi India’s Position and Financial Standing
In response to the statutory communication, Sanofi India stated that it is reviewing the show cause notice in close coordination with its legal and tax advisors. The enterprise confirmed that it will present a comprehensive formal submission within the timeline prescribed by the authority.
The company has stated that it does not foresee any adverse operational or financial disruption stemming from the notice. This stance is supported by the firm’s robust operational footing and balance sheet strength in the domestic healthcare sector.
Engaged in the manufacture and marketing of essential pharmaceutical formulations and vaccines, Sanofi India recently reported healthy earnings growth. On a standalone basis for the quarter ended June 2026 (Q2):
- Net Profit: Rose 20.14% year-on-year to ₹83.50 crore (compared to Q2 June 2025).
- Net Sales: Increased 7.73% year-on-year to ₹437.70 crore.
The market also displayed measured stability around the announcement; shares of Sanofi India closed 0.34% higher at ₹3,143.40 on Friday, September 25, 2026.
Broader Compliance Takeaways for the Pharmaceutical Sector
The pharmaceutical industry maintains complex, multi-echelon distribution networks, active contract manufacturing relationships, and diverse promotional arrangements. These operational structures create extensive transaction volumes that require meticulous invoice matching and strict verification of tax payments down the vendor value chain.
As state GST directorates such as DGSTO Bengaluru intensify data-led audits for historical assessment years like FY2022-23, large corporates are expected to face elevated compliance scrutiny. Successfully rebutting notices issued under Section 73 hinges on producing comprehensive documentary trails, reconciling supplier filings, demonstrating actual receipt of goods and services, and verifying timely tax payment by counterparties.
Sanofi India’s upcoming statutory defense will represent a pivotal procedural step in establishing whether the ₹14.43 crore principal demand can be fully substantiated or resolved through reconciliation before the adjudicating authority.
Frequently Asked Questions
The notice was issued by the Commercial Tax Officer (Audit)-6.1, DGSTO-6, Bengaluru, under Section 73 of the Karnataka Goods and Services Tax Act, 2017.
The total demand is ₹23.74 crore, which includes a proposed tax liability of ₹14.43 crore and interest of ₹9.31 crore.
The notice covers the period from April 2022 to March 2023 (FY2022-23) and alleges that Sanofi India claimed excess input tax credit.
On a standalone basis, Sanofi India recorded a 20.14% increase in net profit to ₹83.50 crore and a 7.73% rise in net sales to ₹437.70 crore compared to Q2 June 2025.
